An observational study in Optic Neuritis, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, sponsored by King's College London. Not yet recruiting at 3 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by King's College London · Observational
Among 12 studies in Neuromyelitis Optica with a site in United Kingdom — 4 open to participants now, 4 under way, 1 of them phase 3. Neuromyelitis Optica · United Kingdom.
Among the 12 studies in Neuromyelitis Optica with a site in United Kingdom, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 12th registered.
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
Browse Neuromyelitis Optica studies →4 of the 12 studies in Neuromyelitis Optica with a site in United Kingdom are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United Kingdom, United States, Argentina and 6 more countries
Alexion Pharmaceuticals, Inc. · Sites in United Kingdom, United States, Australia and 4 more countries
Amgen · Sites in United Kingdom, United States, Argentina and 8 more countries
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 180 is close to the median of 200 across 62 observational studies indexed under Neuromyelitis Optica.
Median enrollment 58 across the 9 interventional studies, 75 across the 3 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 7 most frequent:
King's College London is the lead sponsor of 520 studies on the registry; 126 are open to participants now.
King's College London has 1 study filed under Neuromyelitis Optica — fewer than ten, so there is no comparison to draw.
2 of the studies in Neuromyelitis Optica with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05199688Phase 3Hoffmann-La RocheA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) | 2027-03-31 |
| NCT05549258AmgenStudy of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder | 2027-04-13 |
Among the 12 studies in Neuromyelitis Optica with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to determine whether genetic information, together with clinical information, can be used to improve prediction of future multiple sclerosis (MS) diagnosis after a first-time episode of optic neuritis. The study will also investigate visual outcomes, quality of life, healthcare use, and the acceptability of using genetic information to predict future health outcomes in people with optic neuritis.
The main outcomes that we aim to assess are:
If consented, participants will:
178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.
This study's planned enrollment of 180 is close to the median of 200 across 62 observational studies indexed under Neuromyelitis Optica.
Browse Neuromyelitis Optica studies →King's College London is the lead sponsor of 520 studies on the registry; 126 are open to participants now.
Compared within Neuromyelitis Optica, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Optic Neuritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants aged 16 and above with a history of a first episode of optic neuritis recruited from one of the three participating NHS sites in London (Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Foundation Trust and Moorfields Eye Hospital NHS Foundation Trust)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a history of a first episode of optic neuritis recruited from the 3 participating NHS hospitals. Participants will undergo retrospective review of clinical records, complete questionnaires, and may provide a saliva sample for genetic analysis. Participants will be invited to consent to longer term prospective outcome assessment.
Other: No Intervention: Observational Cohort
Not applicable - No intervention as this is an observation study
Incident Multiple Sclerosis Diagnosis Following a First Episode of Optic Neuritis
Occurrence of a diagnosis of multiple sclerosis following a first episode of optic neuritis.
Time frame: Extracted from retrospective record at baseline, and reviewed before study end to capture any new events occurring during the 12 month study period.
Visual Acuity (LogMAR)
Visual acuity (LogMAR) measured at first diagnosis of optic neuritis and at subsequent follow-up assessments.
Time frame: From the date of first optic neuritis diagnosis until the last available follow-up assessment (up to 15 years).
Visual Field Mean Deviation (dB)
Visual field mean deviation (Decibels) measured at first diagnosis of optic neuritis and at subsequent follow-up assessments
Time frame: From the date of first optic neuritis diagnosis until the last available follow-up assessment (up to 15 years).
Colour Vision (Number of Ishihara Plates Correctly Identified)
Colour vision assessed using Ishihara pseudoisochromatic plates and reported as the number of plates correctly identified.
Time frame: From the date of first optic neuritis diagnosis until the last available follow-up assessment (up to 15 years).
Number of Healthcare Consultations Following Optic Neuritis Diagnosis
Number of healthcare consultations attended following optic neuritis diagnosis, reported by consultation type, including primary care appointments, emergency department attendances, neuro-ophthalmology, neurology, and other relevant specialist clinics.
Time frame: 12 months
Number of Investigations Performed Following Optic Neuritis Diagnosis
Number of investigations performed following optic neuritis diagnosis, reported by investigation type, including OCT, visual field testing, MRI, VEP, blood tests, and CSF analysis.
Time frame: 12 months
Time to Diagnostic Investigations Following Optic Neuritis Diagnosis (Days)
Time interval (days) from optic neuritis diagnosis to each investigation, reported by investigation type.
Time frame: 12 months
Time to Treatment Following Optic Neuritis Diagnosis (Days)
Time interval (Days) from optic neuritis diagnosis to initiation of first treatment course, reported by treatment type.
Time frame: 12 months
Number of Treatment Episodes Following Optic Neuritis Diagnosis
Number of treatment episodes received following optic neuritis diagnosis, reported by treatment type (e.g. intravenous corticosteroids, oral corticosteroids, plasma exchange, intravenous immunoglobulin, disease-modifying therapies).
Time frame: 12 months
Health-Related Quality of Life (EuroQol 5-Dimension 5-Level Questionnaire [EQ-5D-5L])
Health-related quality of life assessed using the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L). The EQ-5D-5L descriptive system comprises five domains, each scored on five levels. Higher levels indicate worse health status and poorer health-related quality of life.
Time frame: Measured at baseline recruitment and repeated 3-12 months later
Vision-Related Quality of Life (National Eye Institute Visual Function Questionnaire-25 [NEI-VFQ-25])
Vision-related quality of life assessed using the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) composite score. Scores range from 0 to 100, with higher scores indicating better vision-related quality of life.
Time frame: Baseline and repeated 3-12 months later
Optic Neuritis-Related Quality of Life (Semi-Structured Questionnaire)
Participant-reported optic neuritis-related quality of life and lived experiences, including symptoms, treatment impacts, emotional well-being, activities of daily living, social participation and personal relationships, explored using a bespoke semi-structured questionnaire
Time frame: Measured at baseline recruitment and repeated 3-12 months later
Fatigue (Patient-Reported Outcomes Measurement Information System [PROMIS] Fatigue 6a)
Fatigue assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 6a instrument. Raw scores are converted to T-scores with a mean of 50 and standard deviation of 10 in the reference population. Higher scores indicate greater fatigue (worse outcome).
Time frame: Baseline recruitment and repeated once 3-12 months later
Depression (Patient-Reported Outcomes Measurement Information System [PROMIS] Depression 4a)
Depression assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression 4a instrument. Raw scores are converted to T-scores with a mean of 50 and standard deviation of 10 in the reference population. Higher scores indicate more severe depressive symptoms (worse outcome).
Time frame: Baseline recruitment and repeated once 3-12 months later
Work Productivity Loss (Adapted iMTA Productivity Cost Questionnaire [iPCQ])
Participant-reported work productivity loss associated with optic neuritis or related diseases, including absenteeism, presenteeism and changes to employment. Measured using the Adapted iMTA Productivity Cost Questionnaire (iPCQ)
Time frame: Baseline recruitment and repeated once 3-12 months later
Healthcare Resource Utilisation: Appointments, Emergency Department Attendances and Hospital Admissions (Adapted iMTA Medical Consumption Questionnaire [iMCQ])
Participant-reported utilisation of healthcare services related to optic neuritis or associated diseases, including appointments with healthcare professionals, emergency department attendances, and hospital admissions
Time frame: Baseline recruitment and repeated once 3-12 months later
Healthcare Resource Utilisation: Investigations and Treatment Interventions (Adapted iMTA Medical Consumption Questionnaire [iMCQ])
Participant-reported utilisation of diagnostic investigations and therapeutic interventions related to optic neuritis or associated diseases, including imaging, laboratory investigations, electrophysiological testing, and treatments received.
Time frame: Baseline recruitment and repeated once 3-12 months later
Informal Care Received (Hours)
Participant-reported hours of informal care received from family members, friends or acquaintances because of optic neuritis or associated diseases.
Time frame: Baseline recruitment and repeated once 3-12 months later
Out-of-Pocket Costs (Pounds Sterling)
Participant-reported personal expenditure related to optic neuritis and associated diseases in the first year after optic neuritis began (e.g. health insurance, prescription costs, optician/sight tests, low vision aids)
Time frame: Baseline recruitment and repeated once 3-12 months later
Knowledge, Attitudes and Practices/Behaviours Regarding Genetic Risk Prediction (KAP Questionnaire)
This will be explored using a knowledge, attitudes and practices/behaviour questionnaire to explore how participants feel about the use of genetic information to predict future health outcome risk including multiple sclerosis.
Time frame: Baseline recruitment and repeated at 3-12 months later
Plan to share: Undecided
Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.